Lava Therapeutics NV DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
LAVA Therapeutics N.V. shareholders are invited to an Extraordinary General Meeting on November 7, 2025, to vote on XOMA Royalty Corporation's amended tender offer of $1.04 cash plus one Contingent Value Right per share.
LAVA Therapeutics and XOMA Royalty amend their share purchase agreement, reducing the cash per share to $1.04 and adjusting contingent value rights, while extending the tender offer and reconvening the EGM.
XOMA Royalty Corporation and LAVA Therapeutics N.V. announced the extension of the tender offer for LAVA's outstanding shares until October 17, 2025.
LAVA Therapeutics N.V. has cancelled its Extraordinary General Meeting to approve the XOMA Royalty Corporation acquisition, rescheduling it for early November 2025 to finalize transaction terms.
LAVA Therapeutics N.V. shareholders are invited to an Extraordinary General Meeting to vote on XOMA Royalty Corporation's offer to acquire all outstanding shares for cash and contingent value rights, a deal unanimously recommended by LAVA's Board.
XOMA Royalty Corporation has commenced a tender offer to acquire LAVA Therapeutics N.V. for $1.16 to $1.24 per share plus a contingent value right.
XOMA Royalty Corporation will acquire LAVA Therapeutics N.V. for a cash consideration of $1.16 to $1.24 per share plus a contingent value right, following a unanimous recommendation from LAVA's Board.
LAVA Therapeutics N.V. has filed an amended definitive proxy statement for its 2025 Annual General Meeting, notably proposing a change in its external auditor from PricewaterhouseCoopers to KPMG for the 2025 financial year and addressing previously remediated material weaknesses in internal controls.
LAVA Therapeutics N.V. announces its 2025 Annual General Meeting (AGM) to be held on June 11, 2025, in Utrecht, the Netherlands, featuring proposals ranging from the adoption of annual accounts to the reappointment of non-executive directors.